Onco Actu du 15 juin 2017

	1. Biologie
Five reasons we’re excited by how structural biology is advancing cancer research [Institute of Cancer Research] We’re interested in finding out what a protein looks like in three dimensions, to better understand its function and how, in cancer cells, it can go wrong.
	2.6 Etiologie - Environnement
Cancer agency left in the dark over glyphosate evidence [Reuters] The World Health Organization's cancer agency says a common weedkiller is "probably carcinogenic." The scientist leading that review knew of fresh data showing no cancer link - but he never mentioned it and the agency did not take it into account.
	2.9 Etiologie - Tabac
Where Cigarette Smoking’s Damage is Done . . . Down to Your DNA [UNC] A new technique from UNC School of Medicine scientists led by Nobel Prize winner Aziz Sancar reveals the genome-wide DNA damage that a major carcinogen causes.
	3.5 Prévention - UV
Scientists have created a ‘sunless tanner’ drug that boosts melanin in skin [STAT] "We discovered a class of compounds that have the ability to penetrate into the skin and trigger pigmentation."
	5. Traitements
Scientists Look in the Toilet in Search for New Cancer Treatment [Bloomberg] New research suggests a link between the trillions of bugs that inhabit the bowels and the effectiveness of immune therapies--drugs that tap the body’s defenses to fight tumors. That has spurred companies worldwide to start delving into patients’ stools in search of a better understanding of microbes in the digestive system.
Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer [NCI] - EMILIA trial : patients given T-DM1 had longer median overall survival than patients in the control group—29.9 months, versus 25.9 months for those treated with lapatinib plus capecitabine. - TH3RESA trial : patients receiving T-DM1 had a median overall survival of 22.7 months, compared with 15.8 months for patients receiving other third-line therapy.
	5.12.2 Immunothérapies - CAR-T
With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now [EndPoints] According to Juno, the court determined that there was no evidence that an FDA approval of Kite’s therapy – axicabtagene ciloleucel, or KTE-C19 – “is imminent or even certain.” So the suit was dismissed.
	5.2 Pharma
Epizyme shares slump as cancer drug data update disappoints [EndPoints] Initially, observers had been pleased by the 40% overall response rate that researchers had been tracking on DLBCL for its EZH2 inhibitor. Then this morning the company provided an update on their Phase II with more patients in the mix, and the ORR dropped to 29%.
	5.2.3 Pharma - économie
Novartis, Verily back $300M Medicxi biotech growth fund [FierceBiotech] Novartis, Alphabet’s Verily—the firm formerly known as Google Life Sciences—and the European Investment Fund (EIF) are the cornerstone investors in the fund.
Athenex IPO Raises $66M to Fund Clinical Trials for Cancer Drugs [Xconomy] Athenex is already planning to seek approval of its oral paclitaxel overseas.
With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope [EndPoints] Google more broadly, he adds, has identified healthcare as a huge field they would like to gradually build their business in. This new fund extends Verily’s reach in Europe.
Google bets on European biotech drugs, backs new fund [Reuters] The new fund will back both private and public firms with products that have already reached mid-stage Phase II clinical development, providing them with a new source of growth capital.
	5.3 Traitements - FDA, EMA, NICE...
EMA – PRAC Concludes There Is No Evidence of a Change in Known Risk of Neutropenic Enterocolitis With Docetaxel [ESMO] Having considered available data on docetaxel, the Committee concluded that the recent rise in reporting of the condition observed in France could be due to an increased awareness among healthcare professionals.
	5.4 Traitements - Economie
Multiple myeloma patients to get NHS access to Amgen’s Kyprolis [PharmaTimes] Kyprolis (carfilzomib) is an intravenously-administered irreversible proteasome inhibitor that binds to the N-terminal threonine site, causing degradation of the proteins in the cell.
NICE rejects Pfizer’s ALL drug Besponsa [PharmaTimes] Besponsa (inotuzumab) is an antibody drug conjugate which is comprised of a monoclonal antibody targeting CD22, a cell surface antigen expressed on around 90 percent of B-cell malignancies, linked to a cytotoxic agent.
	6.10.1 Politiques (USA)
Trump White House at work on executive order tackling drug prices: report [FiercePharma] The White House is working on an executive order on the issue, according to BioCentury, with eyes on value-based contracting for executive agencies. The executive order would also seek trade policies that protect American drugmakers’ intellectual property rights abroad, according to BioCentury’s sources.
	6.5 Médecines alternatives
Complementary and integrative medicine for cancer patients – A purely ideological debate? [Cancer World] It is easy for a doctor to dismiss it as unproven quackery, but very difficult then to give an answer to cancer patients in pain, with impossible nausea and vomiting, with drug-resistant permanent insomnia, with weight loss and cachexia, who are open to any reasonable solution in the hope of feeling better.
	6.7 DMP, Big Data & applis
QuintilesIMS partners with NHS Cancer Vanguard [PharmaTimes] The collaboration aims to seamlessly infuse QuintilesIMS insights into practice management to optimise medicines use, and to use real world data to transform the colorectal cancer patient pathway to improve clinical outcomes and patient experience.
Apple is quietly working on turning your iPhone into the one-stop shop for all your medical info [CNBC] CNBC has learned that a secretive team within Apple's growing health unit has been in talks with developers, hospitals and other industry groups about bringing clinical data, such as detailed lab results and allergy lists, to the iPhone, according to a half-dozen people familiar with the team. And from there, users could choose to share it with third parties, like hospitals and health developers.
	6.7.1 Bioinformatique
Artificial intelligence may help doctors keep up with new research [Reuters] The machine-learning method missed only two articles that humans would have identified, for an overall accuracy of 96 percent. And neither of these articles would have changed the ultimate evidence reviews, Shekelle’s team concludes.